多组学技术及其在肝细胞癌中的临床应用：当前进展与未来机遇

doi:10.24920/003984

Chinese Medical Sciences Journal ›› 2021, Vol. 36 ›› Issue (3): 173-186.doi: 10.24920/003984

所属专题：人工智能与精准肿瘤学

多组学技术及其在肝细胞癌中的临床应用：当前进展与未来机遇

杨万水¹,蒋涵羽²,刘超^3,⁴,魏靖伟^5,^6,⁷,周宇^5,^6,^7,⁸,宫鹏云^3,⁴,宋彬^2,^*(),田捷^3,^4,^5,^6,^9,^*()

¹安徽医科大学公共卫生学院营养与食品卫生学系,合肥 230032,中国
²四川大学华西医院放射科,成都 610041,中国
³北京航空航天大学北京大数据与精准医疗高精尖创新中心,北京 100191,中国
⁴北京航空航天大学大数据精准医疗工信部重点实验室,北京 100191,中国
⁵中国科学院自动化研究所中国科学院分子影像重点实验室,北京 100190,中国
⁶分子影像北京市重点实验室,北京 100190,中国
⁷中国科学院大学,北京 100049,中国
⁸西安电子科技大学生命科学学院,西安 710126, 中国
⁹西安电子科技大学生命科学技术学院和分子与神经影像教育部工程研究中心,西安 710126, 中国

收稿日期:2021-08-16 接受日期:2021-09-14 出版日期:2021-09-30 发布日期:2021-09-17
通讯作者: 宋彬,田捷 E-mail:anicesong@vip.sina.com;jie.tian@ia.ac.cn

Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities

Wanshui Yang¹,Hanyu Jiang²,Chao Liu^3,⁴,Jingwei Wei^5,^6,⁷,Yu Zhou^5,^6,^7,⁸,Pengyun Gong^3,⁴,Bin Song^2,^*(),Jie Tian^3,^4,^5,^6,^9,^*()

¹Department of Nutrition, School of Public Health, Anhui Medical University, Hefei 230032, China
²Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China
³Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing 100191, China
⁴Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing 100191, China
⁵Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China
⁶Beijing Key Laboratory of Molecular Imaging, Beijing 100190, China
⁷University of Chinese Academy of Sciences, Beijing 100049, China
⁸School of Life Science and Technology, Xidian University, Xi’an 710126, China
⁹Engineering Research Center of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710126, China

Received:2021-08-16 Accepted:2021-09-14 Published:2021-09-30 Online:2021-09-17
Contact: Bin Song,Jie Tian E-mail:anicesong@vip.sina.com;jie.tian@ia.ac.cn

1. Most commenly used feature selection algorithms in radiomics studies.pdf(193KB)

摘要/Abstract

摘要：

全球范围内,肝细胞癌(Hepatocellular carcinoma, HCC)是第六大常见恶性肿瘤,也是癌症相关死亡的第四大原因。中国HCC病例占全球病例的50%以上,导致HCC成为重要的公共卫生问题。尽管HCC诊断和治疗取得了进步,但高复发率仍然是HCC治愈的主要障碍。目前,多组学技术的融合促进了临床上疾病的监测、精准诊断和个体化治疗。无创的影像组学利用术前影像图像反映特定临床结局相关的细微像素级的模式变化。影像组学已广泛应用于预测组织病理学诊断、评估治疗反应和预测疾病预后。高通量测序技术和基因表达谱分析使基因组学和蛋白质组学能够识别HCC中不同的转录组亚型和反复性的遗传改变,这将揭示病理生理学上复杂的疾病发生过程。医学大数据的积累和人工智能技术的发展使我们更好地从多组学的角度深入理解HCC的发病机制,并显示出将HCC的外科治疗或介入治疗转化为抗肿瘤发生机制治疗的潜力,这将极大地推动HCC精准诊疗的发展。

关键词: 肝细胞癌, 影像组学, 蛋白质组学, 基因组学, 多组学

Abstract:

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the fourth leading cause of cancer related death worldwide. China covers over half of cases, leading HCC to be a vital threaten to public health. Despite advances in diagnosis and treatments, high recurrence rate remains a major obstacle in HCC management. Multi-omics currently facilitates surveillance, precise diagnosis, and personalized treatment decision making in clinical setting. Non-invasive radiomics utilizes preoperative radiological imaging to reflect subtle pixel-level pattern changes that correlate to specific clinical outcomes. Radiomics has been widely used in histopathological diagnosis prediction, treatment response evaluation, and prognosis prediction. High-throughput sequencing and gene expression profiling enabled genomics and proteomics to identify distinct transcriptomic subclasses and recurrent genetic alterations in HCC, which would reveal the complex multistep process of the pathophysiology. The accumulation of big medical data and the development of artificial intelligence techniques are providing new insights for our better understanding of the mechanism of HCC via multi-omics, and show potential to convert surgical/intervention treatment into an antitumorigenic one, which would greatly advance precision medicine in HCC management.

Key words: hepatocellular carcinoma, radiomics, proteomics, genomics, multi-omics

Wanshui Yang, Hanyu Jiang, Chao Liu, Jingwei Wei, Yu Zhou, Pengyun Gong, Bin Song, Jie Tian. Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities[J].Chinese Medical Sciences Journal, 2021, 36(3): 173-186.

图/表 2

参考文献 96.

1.	Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016; 2:16018. doi: 10.1038/nrdp.2016.18. doi: 10.1038/nrdp.2016.18
2.	McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015; 19(2):223-38. doi: 10.1016/j.cld.2015.01.001. doi: 10.1016/j.cld.2015.01.001
3.	International Agency for Research on Cancer. GLOBOCAN 2018. Estimated age-standardized incidence rates (World) in 2020, liver, both sexes, all ages. Available from https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=11&type=0&statistic=5&prevalence=0&population_groupearth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D (2020). Accessed August 16, 2021.
4.	Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015; 261(5):947-55. doi: 10.1097/SLA.0000000000000710. doi: 10.1097/SLA.0000000000000710
5.	Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68(2):723-50. doi: 10.1002/hep.29913. doi: 10.1002/hep.29913
6.	Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017; 14(12):749-62. doi: 10.1038/nrclinonc.2017.141. doi: 10.1038/nrclinonc.2017.141
7.	Wei J, Jiang H, Gu D, et al. Radiomics in liver diseases: Current progress and future opportunities. Liver Int 2020; 40(9):2050-63. doi: 10.1111/liv.14555. doi: 10.1111/liv.14555
8.	Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY) 2017; 42(6):1695-704. doi: 10.1007/s00261-017-1072-0. doi: 10.1007/s00261-017-1072-0
9.	Cozzi L, Dinapoli N, Fogliata A, et al. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer 2017; 17(1):829. doi: 10.1186/s12885-017-3847-7. doi: 10.1186/s12885-017-3847-7
10.	Naganawa S, Enooku K, Tateishi R, et al. Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. Eur Radiol 2018; 28(7):3050-8. doi: 10.1007/s00330-017-5270-5. doi: 10.1007/s00330-017-5270-5
11.	Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003; 23(6):405-9. doi: 10.1111/j.1478-3231.2003.00869.x. doi: 10.1111/j.1478-3231.2003.00869.x
12.	Seehawer M, Heinzmann F, D’Artista L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature 2018; 562(7725):69-75. doi: 10.1038/s41586-018-0519-y. Erratum in Nature 2018; 564(7735):E9. doi 10.1038/s41586-018-0723-9. doi: 10.1038/s41586-018-0723-9
13.	Yuan D, Huang S, Berger E, et al. Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell 2017; 31(6):771- 89. e6. doi: 10.1016/j.ccell.2017.05.006. doi: 10.1016/j.ccell.2017.05.006
14.	Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 2017; 152(4):745-61. doi: 10.1053/j.gastro.2016.11.048. doi: 10.1053/j.gastro.2016.11.048
15.	Li Z, Mao Y, Huang W, et al. Texture-based classification of different single liver lesion based on SPAIR T2W MRI images. BMC Med Imaging 2017; 17(1):42. doi: 10.1186/s12880-017-0212-x. doi: 10.1186/s12880-017-0212-x
16.	Trivizakis E, Manikis GC, Nikiforaki K, et al. Extending 2-D convolutional neural networks to 3-D for advancing deep learning cancer classification with application to MRI liver uumor differentiation. IEEE J Biomed Health Inform 2019; 23(3):923-30. doi: 10.1109/JBHI.2018.2886276. doi: 10.1109/JBHI.2018.2886276
17.	Jiang H, Liu X, Chen J, et al. Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. Cancer Imaging 2019; 19(1):84. doi: 10.1186/s40644-019-0266-9. doi: 10.1186/s40644-019-0266-9
18.	Yao Z, Dong Y, Wu G, et al. Preoperative diagnosis and prediction of hepatocellular carcinoma: radiomics analysis based on multi-modal ultrasound images. BMC Cancer 2018; 18(1):1089. doi: 10.1186/s12885-018-5003-4. doi: 10.1186/s12885-018-5003-4
19.	Cucchetti A, Piscaglia F, Grigioni AD, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol 2010; 52(6):880-8. doi: 10.1016/j.jhep.2009.12.037. doi: 10.1016/j.jhep.2009.12.037
20.	Zhou W, Zhang L, Wang K, et al. Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging 2017; 45(5):1476-84. doi: 10.1002/jmri.25454. doi: 10.1002/jmri.25454
21.	Wu M, Tan H, Gao F, et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol 2019; 29(6):2802-11. doi: 10.1007/s00330-018-5787-2. doi: 10.1007/s00330-018-5787-2
22.	Ye Z, Jiang H, Chen J, et al. Texture analysis on doi: 10.21147/j.issn.1000-9604.2019.05.10
	gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: a prospective study. Chin J Cancer Res 2019; 31(5):806-17. doi: 10.21147/j.issn.1000-9604.2019.05.10. doi: 10.21147/j.issn.1000-9604.2019.05.10
23.	Wei J, Jiang H, Zeng M, et al. Prediction of microvascular invasion in hepatocellular carcinoma via deep learning: a multi-center and prospective validation study. Cancers (Basel) 2021; 13(10):2368. doi: 10.3390/cancers13102368. doi: 10.3390/cancers13102368
24.	Xu X, Zhang HL, Liu QP, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol 2019; 70(6):1133-44. doi: 10.1016/j.jhep.2019.02.023. doi: 10.1016/j.jhep.2019.02.023
25.	Banerjee S, Wang DS, Kim HJ, et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 2015; 62(3):792-800. doi: 10.1002/hep.27877. doi: 10.1002/hep.27877
26.	Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018; 19(9):1180-91. doi: 10.1016/S1470-2045(18)30413-3. doi: 10.1016/S1470-2045(18)30413-3
27.	Chen S, Feng S, Wei J, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 2019; 29(8):4177-87. doi: 10.1007/s00330-018-5986-x. doi: 10.1007/s00330-018-5986-x
28.	Hectors SJ, Lewis S, Besa C, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol 2020; 30(7):3759-69. doi: 10.1007/s00330-020-06675-2. doi: 10.1007/s00330-020-06675-2
29.	Yuan C, Wang Z, Gu D, et al. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a radiomics nomogram. Cancer Imaging 2019; 19(1):21. doi: 10.1186/s40644-019-0207-7. doi: 10.1186/s40644-019-0207-7
30.	Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 2020; 294(3):568-79. doi: 10.1148/radiol.2020191470. doi: 10.1148/radiol.2020191470
31.	Hui TCH, Chuah TK, Low HM, et al. Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study. Clin Radiol 2018; 73(12):1056. e11- 1056. e16. doi: 10.1016/j.crad.2018.07.109. doi: 10.1016/j.crad.2018.07.109
32.	Park HJ, Kim JH, Choi SY, et al. Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization based on pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol 2017; 209(4):w211-w220. doi: 10.2214/AJR.16.17398. doi: 10.2214/AJR.16.17398
33.	Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol 2018; 211(5):1026-34. doi: 10.2214/AJR.18.19507. doi: 10.2214/AJR.18.19507
34.	Blanc-Durand P, van der Gucht A, Jreige M, et al. Signature of survival: a ¹⁸F-FDG PET based whole-liver radiomic analysis predicts survival after ⁹⁰Y-TARE for hepatocellular carcinoma. Oncotarget 2017; 9(4):4549-58. doi: 10.18632/oncotarget.23423. doi: 10.18632/oncotarget.23423
35.	Mulé S, Thiefin G, Costentin C, et al. Advanced hepatocellular carcinoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with sorafenib. Radiology 2018; 288(2):445-55. doi: 10.1148/radiol.2018171320. doi: 10.1148/radiol.2018171320
36.	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7(1):6. doi: 10.1038/s41572-020-00240-3. doi: 10.1038/s41572-020-00240-3
37.	Calderaro J, Ziol M, Paradis V, et al. Molecular and histological correlations in liver cancer. J Hepatol 2019; 71(3):616-30. doi: 10.1016/j.jhep.2019.06.001. doi: 10.1016/j.jhep.2019.06.001
38.	Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015; 149(5):1226- 39.e4. doi: 10.1053/j.gastro.2015.05.061. doi: 10.1053/j.gastro.2015.05.061
39.	Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014; 46(12):1267-73. doi: 10.1038/ng.3126. doi: 10.1038/ng.3126
40.	Ahn SM, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014; 60(6):1972-82. doi: 10.1002/hep.27198. doi: 10.1002/hep.27198
41.	Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47(5):505-11. doi: 10.1038/ng.3252. doi: 10.1038/ng.3252
42.	Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44(6):694-8. doi: 10.1038/ng.2256. doi: 10.1038/ng.2256
43.	Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013; 4:2218. doi: 10.1038/ncomms3218. Erratum in Nat Commun 2013; 4:2577. doi 10.1038/ncomms3577. doi: 10.1038/ncomms3577
44.	Paterlini-Bréchot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003; 22(25):3911-6. doi: 10.1038/sj.onc.1206492. doi: 10.1038/sj.onc.1206492
45.	Bayard Q, Meunier L, Peneau C, et al. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nat Commun 2018; 9(1):5235. doi: 10.1038/s41467-018-07552-9. doi: 10.1038/s41467-018-07552-9
46.	Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68(16):6779-88. doi: 10.1158/0008-5472.CAN-08-0742. doi: 10.1158/0008-5472.CAN-08-0742
47.	Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350(6317):429-31. doi: 10.1038/350429a0. doi: 10.1038/350429a0
48.	Wang B, Huang G, Wang D, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol 2010; 53(3):508-18. doi: 10.1016/j.jhep.2010.03.026. doi: 10.1016/j.jhep.2010.03.026
49.	Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40(12):1461-5. doi: 10.1038/ng.257. doi: 10.1038/ng.257
50.	Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015; 47(12):1443-8. doi: 10.1038/ng.3417. doi: 10.1038/ng.3417
51.	Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020; 72(2):215-29. doi: 10.1016/j.jhep.2019.08.017. doi: 10.1016/j.jhep.2019.08.017
52.	Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69(18):7385-92. doi: 10.1158/0008-5472.CAN-09-1089. doi: 10.1158/0008-5472.CAN-09-1089
53.	Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017; 169(7):1327- 41. e23. doi: 10.1016/j.cell.2017.05.046. doi: 10.1016/j.cell.2017.05.046
54.	Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12(4):410-6. doi: 10.1038/nm1377. doi: 10.1038/nm1377
55.	Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45(1):42-52. doi: 10.1002/hep.21467. doi: 10.1002/hep.21467
56.	Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 2017; 153(3):812-26. doi: 10.1053/j.gastro.2017.06.007. doi: 10.1053/j.gastro.2017.06.007
57.	Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018; 15(10):599-616. doi: 10.1038/s41571-018-0073-4. doi: 10.1038/s41571-018-0073-4
58.	Erstad DJ, Fuchs BC, Tanabe KK. Molecular signatures in hepatocellular carcinoma: a step toward rationally designed cancer therapy. Cancer 2018; 124(15):3084-104. doi: 10.1002/cncr.31257. doi: 10.1002/cncr.31257
59.	Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40(3):667-76. doi: 10.1002/hep.20375. doi: 10.1002/hep.20375
60.	Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017; 67(4):727-38. doi: 10.1016/j.jhep.2017.05.014. doi: 10.1016/j.jhep.2017.05.014
61.	Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012; 18(18):4997-5007. doi: 10.1158/1078-0432.CCR-11-2322. doi: 10.1158/1078-0432.CCR-11-2322
62.	Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, et al. β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov 2019; 9(8):1124-41. doi: 10.1158/2159-8290.CD-19-0074. doi: 10.1158/2159-8290.CD-19-0074
63.	Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131(2):461-9. doi: 10.1053/j.gastro.2006.05.021. doi: 10.1053/j.gastro.2006.05.021
64.	Lazcano G, Papuzinski C, Madrid E, et al. General concepts in biostatistics and clinical epidemiology: observational studies with cohort design. Medwave 2019; 19(11):e7748. Spanish and English. doi: 10.5867/medwave.2019.11.7748. doi: 10.5867/medwave.2019.11.7748
65.	Kim S, Shin J, Kim DY, et al. Radiomics on Gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 2019; 25(13):3847-55. doi: 10.1158/1078-0432.CCR-18-2861. doi: 10.1158/1078-0432.CCR-18-2861
66.	Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002; 359(9303):341-5. doi: 10.1016/S0140-6736(02)07500-1. doi: 10.1016/S0140-6736(02)07500-1
67.	Font C, Carmona-Bayonas A, Beato C, et al. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J 2017; 49(1):1600282. doi: 10.1183/13993003.00282-2016. doi: 10.1183/13993003.00282-2016
68.	Liu L, Nevo D, Nishihara R, et al. Utility of inverse probability weighting in molecular pathological epidemiology. Eur J Epidemiol 2018; 33(4):381-92. doi: 10.1007/s10654-017-0346-8. doi: 10.1007/s10654-017-0346-8
69.	Dettori JR. Loss to follow-up. Evid Based Spine Care J 2011; 2(1):7-10. doi: 10.1055/s-0030-1267080. doi: 10.1055/s-0030-1267080
70.	Ferreira JC, Patino CM. Loss to follow-up and missing data: important issues that can affect your study results. J Bras Pneumol 2019; 45(2):e20190091. doi: 10.1590/1806-3713/e20190091. doi: 10.1590/1806-3713/e20190091
71.	Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60(3):397-411. doi: 10.1136/gut.2010.217182. doi: 10.1136/gut.2010.217182
72.	López de Maturana E, Alonso L, Alarcón P, et al. Challenges in the integration of omics and non-omics data. Genes (Basel) 2019; 10(3):238. doi: 10.3390/genes10030238. doi: 10.3390/genes10030238
73.	López de Maturana E, Pineda S, Brand A, et al. Toward the integration of Omics data in epidemiological studies: still a “long and winding road”. Genet Epidemiol 2016; 40(7):558-69. doi: 10.1002/gepi.21992. doi: 10.1002/gepi.21992
74.	Lehmann TM, Gönner C, Spitzer K. Survey: interpolation methods in medical image processing. IEEE Trans Med Imaging 1999; 18(11):1049-75. doi: 10.1109/42.816070. doi: 10.1109/42.816070
75.	Lehmann T, Oberschelp W, Pelikan E, et al. Bildverarbeitung für die Medizin: Grundlagen, Modelle, Methoden, Anwendungen. Berlin, Heidelberg: Springer-Verlag; 2013. German. doi: 10.1007/978-3-642-60487-4. doi: 10.1007/978-3-642-60487-4
76.	Yang Q, Wei J, Hao X, et al. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: a multicentre study. EBioMedicine 2020; 56:102777. doi: 10.1016/j.ebiom.2020.102777. doi: 10.1016/j.ebiom.2020.102777
77.	Zhao M, Zhang Z, Chow TWS. Trace ratio criterion based generalized discriminative learning for semi-supervised dimensionality reduction. Pattern Recognit 2012; 45(4):1482-99. doi: 10.1016/j.patcog.2011.10.008. doi: 10.1016/j.patcog.2011.10.008
78.	Zhao Z, Liu H. Spectral feature selection for supervised and unsupervised learning. ICML 2007: Proceedings of the 24th international conference on machine learning. June 20-24, 2007; Corvalis Oregon, USA. Vol. 227. p. 1151-1157. doi: 10.1145/1273496.1273641. doi: 10.1145/1273496.1273641
79.	Nie F, Huang H, Cai X, et al. Efficient and robust feature selection via Joint _2, 1-Norms Minimization. In: NIPS 2010: Proceedings of the 23rd International Conference on Neural Information Processing Systems. December 6-11, 2010; Vancouver, Cananda. Vol 2.p. 1813-1821.
80.	Cai D, Zhang C, He X. Unsupervised Feature Selection for Multi-Cluster Data. Proceedings of the 16th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. KDD 2010. July 25-28, 2010; Washington DC, USA. 2010. p. 333-342. doi: 10.1145/1835804.1835848. doi: 10.1145/1835804.1835848
81.	Zhang P, Feng J, Wu X, et al. Bioinformatics analysis of candidate genes and pathways related to hepatocellular carcinoma in China: a study based on public databases. Pathol Oncol Res 2021; 27:588532. doi: 10.3389/pore.2021.588532. doi: 10.3389/pore.2021.588532
82.	Zhou X, Shi M, Cao J, et al. S100 calcium binding protein A10, a novel oncogene, promotes the proliferation, invasion, and migration of hepatocellular carcinoma. Front Genet 2021; 12:695036. doi: 10.3389/fgene.2021.695036. doi: 10.3389/fgene.2021.695036
83.	Chen DB, Xie XW, Zhao YJ, et al. RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A. Sci Rep 2020; 10(1):14538. doi: 10.1038/s41598-020-71403-1. doi: 10.1038/s41598-020-71403-1
84.	Huo J, Wu L, Zang Y. Construction and validation of a reliable six-gene prognostic signature based on the TP53 alteration for hepatocellular carcinoma. Front Oncol 2021; 11:618976. doi: 10.3389/fonc.2021.618976. doi: 10.3389/fonc.2021.618976
85.	Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021; 184(2):404- 21. e16. doi: 10.1016/j.cell.2020.11.041. doi: 10.1016/j.cell.2020.11.041
86.	Li N, Long Y, Fan X, et al. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res 2009; 28(1):122. doi: 10.1186/1756-9966-28-122. doi: 10.1186/1756-9966-28-122
87.	Wei D, Zeng Y, Xing X, et al. Proteome differences between hepatitis B Virus genotype-B- and genotype-C-induced hepatocellular carcinoma revealed by iTRAQ-based quantitative proteomics. J Proteome Res 2016; 15(2):487-98. doi: 10.1021/acs.jproteome.5b00838. doi: 10.1021/acs.jproteome.5b00838
88.	Du Z, Liu X, Wei X, et al. Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma. Sci Rep 2020; 10(1):15552. doi: 10.1038/s41598-020-72510-9. doi: 10.1038/s41598-020-72510-9
89.	Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 2019; 179(2): 561- 77. e22. doi: 10.1016/j.cell.2019.08.052. Erratum in: Cell 2019; 179(5):1240. doi 10.1016/j.cell.2019.10.038. doi: 10.1016/j.cell.2019.10.038
90.	Zhang F, Wang Y, Chen G, et al. Growing human hepatocellular tumors undergo a global metabolic reprogramming. Cancers (Basel) 2021; 13(8):1980. doi: 10.3390/cancers13081980. doi: 10.3390/cancers13081980
91.	Lu S, Cai S, Peng X, et al. Integrative transcriptomic, proteomic and functional analysis reveals ATP1B3 as a diagnostic and potential therapeutic target in hepatocellular carcinoma. Front Immunol 2021; 12:636614. doi: 10.3389/fimmu.2021.636614. doi: 10.3389/fimmu.2021.636614
92.	Wang L, Zhang Z, Li Y, et al. Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. Aging (Albany NY) 2020; 13(2):2480-505. doi: 10.18632/aging.202281. doi: 10.18632/aging.202281
93.	Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007; 25(6):675-80. doi: 10.1038/nbt1306. doi: 10.1038/nbt1306
94.	McCague C, Beer L. Radioproteomics in patients with ovarian cancer. Br J Radiol 2021; 94(1125):20201331. doi: 10.1259/bjr.20201331. doi: 10.1259/bjr.20201331
95.	Badic B, Tixier F, Cheze Le Rest C, et al. Radiogenomics in colorectal cancer. Cancers (Basel) 2021; 13(5):973. doi: 10.3390/cancers13050973. doi: 10.3390/cancers13050973
96.	Lo Gullo R, Daimiel I, Morris EA, et al. Combining molecular and imaging metrics in cancer: radiogenomics. Insights Imaging 2020; 11(1):1. doi: 10.1186/s13244-019-0795-6. doi: 10.1186/s13244-019-0795-6

[1]	陆进,安韶光,马俊杰,杨月,张磊,俞鹏,陶恒,陈云帆,张浩轩. TOP2A基因对预测肝细胞癌预后的作用[J]. Chinese Medical Sciences Journal, 2022, 37(4): 331-339.
[2]	李佳铮, 唐磊. 影像组学在抗肿瘤药物临床试验疗效评估中的应用和挑战[J]. Chinese Medical Sciences Journal, 2021, 36(3): 187-195.
[3]	陈琼,阳学风. 肝细胞癌靶向治疗研究进展[J]. Chinese Medical Sciences Journal, 2021, 36(1): 57-65.
[4]	许艳红,杨嘉,孟捷,王悍. 应用T1加权超微小氧化铁纳米颗粒进行早期肝癌靶向磁共振成像的体内外研究[J]. Chinese Medical Sciences Journal, 2020, 35(2): 142-150.
[5]	吴建强, 秦伟伟, 潘利, 王小蓉, 张彪, 单广良, 高友鹤. 中国不同地区健康人尿液蛋白质组的地域差异[J]. Chinese Medical Sciences Journal, 2019, 34(3): 157-167.
[6]	董德鑫, 纪志刚, 李汉忠, 严维刚, 张玉石. 磁珠联合基质辅助激光解吸电离飞行时间质谱技术检测肾透明细胞癌尿液差异蛋白的初步应用[J]. Chinese Medical Sciences Journal, 2017, 32(4): 248-252.

优先出版

当期目次

过刊浏览

虚拟专题

作者中心

评阅者中心

多组学技术及其在肝细胞癌中的临床应用：当前进展与未来机遇

Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities

RichHTML

PDF (PC)

补充材料

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 96.

相关文章 6

Metrics

推荐阅读 10